IL17A and inflammatory bowel disease: Nevertheless, efforts to impede IL‐17A signaling in inflammatory bowel disease, such as Crohn's disease, through the use of antibodies (such as secukinumab, brodalumab, or ixekizumab) have encountered constrained success, frequently resulting in the exacerbation of inflammation.